Market Overview

Teva Announces Favorable United Kingdom Court Ruling In COPAXONE® Patent Litigation Proceeding

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc., on July 11, 2012. Generics (UK) Limited commenced the proceeding in the UK to seek the revocation of European Patent (UK) 762,888, a patent for COPAXONE® (glatiramer acetate injection) expiring May 23, 2015, and to obtain a declaration that its proposed generic version of COPAXONE® would not infringe the ‘888 patent. The High Court specifically determined that the asserted claims of the ‘888 patent were valid, and also declined to issue a declaration that Generics UK's proposed generic version of COPAXONE® would not infringe the ‘888 patent.

Posted-In: News FDA Global

 

Related Articles (TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters